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Background Supraventricular tachycardia (SVT) is a common heart rhythm 
disorder. The Valsalva Manoeuvre (VM) is a safe, internationally 
recommended, initial treatment, but has a low success rate in normal practice. 
Recent studies have shown much better cardioversion rates, approaching 
50%, can be achieved using a postural modification (the modified VM) and a 
manometer controlled 40 mmHg strain. Successful cardioversion could avoid 
hospital conveyance and unpleasant treatments, such as adenosine. Routine 
use of a manometer is not practical out of hospital. Blowing on an empty 
syringe has been suggested as an alternative but is unreliable in providing 
correct and consistent pressures. A Valsalva Assist Device (VAD), designed 
to provide a 40 mmHg strain resistance has been developed. It is small, 
portable, can be packaged with instructions for the modified VM and if 
successful, may be left with the patient. 
Methods We conducted a pragmatic, randomised controlled feasibility trial, 
comparing VAD versus standard practice delivered VMs. All other aspects of 
care were according to SWASFT guidelines. Participants were followed up to 
ask their views on trial procedures. 
Interim results (month 5 of 6) 23 volunteer Station Leads recruited 22 Study 
Clinicians from 27 ambulance stations. 29 patients were enrolled over 5 
months, 19 in the last 2 months (the first 3 months included steady recruitment 
and setup). The later enrolment rate extrapolates to a presentation rate of 
approximately 220 eligible patients to SWASFT each year. Complete data 
sets were available in 100% of participants. When followed up, participants 
reported verbal consent to be widely acceptable, although SVT symptoms 
were substantially distracting for many during this process. 
Conclusion Our experience of recruitment and data collection suggest a 
definitive trial, using similar methodology, is possible, but the low occurrence 
rate may challenge feasibility. Consent taking methods may require 
refinement for a larger trial. 
